Literature DB >> 2352258

Statistical analysis of the two stage mutation model in von Hippel-Lindau disease, and in sporadic cerebellar haemangioblastoma and renal cell carcinoma.

E R Maher1, J R Yates, M A Ferguson-Smith.   

Abstract

Analysis of the age incidence curves for unilateral and bilateral retinoblastoma led Knudson to propose that hereditary tumours may arise by a single event and sporadic tumours by a two stage mutation process. It has been suggested recently that sporadic renal cell carcinoma may arise from a two stage mutation process. We analysed the age incidence curves for symptomatic renal cell carcinoma (n = 26) and cerebellar haemangioblastoma (n = 68) in 109 patients with von Hippel-Lindau (VHL) disease, and compared them to 104 patients with sporadic renal cell carcinoma and 43 patients with sporadic cerebellar haemangioblastoma. The age incidence curves for renal cell carcinoma and cerebellar haemangioblastoma in VHL disease were compatible with a single mutation model, whereas the age incidence curves for sporadic renal cell carcinoma and cerebellar haemangioblastoma suggested a two stage mutation process. These data are compatible with the VHL gene functioning as a recessive tumour suppressor gene. Sporadic cerebellar haemangioblastoma and some renal cell carcinoma may arise from somatic mutations inactivating both alleles at the VHL locus.

Entities:  

Mesh:

Year:  1990        PMID: 2352258      PMCID: PMC1017082          DOI: 10.1136/jmg.27.5.311

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  21 in total

1.  LINDAU'S DISEASE. REVIEW OF THE LITERATURE AND STUDY OF A LARGE KINDRED.

Authors:  K L MELMON; S W ROSEN
Journal:  Am J Med       Date:  1964-04       Impact factor: 4.965

2.  Von Hippel-Lindau disease: clinical and pathological manifestations in nine families with 50 affected members.

Authors:  W A Horton; V Wong; R Eldridge
Journal:  Arch Intern Med       Date:  1976-07

3.  Mutation and cancer: a model for Wilms' tumor of the kidney.

Authors:  A G Knudson; L C Strong
Journal:  J Natl Cancer Inst       Date:  1972-02       Impact factor: 13.506

4.  Familial renal cell carcinoma with a 3;11 chromosome translocation limited to tumor cells.

Authors:  S Pathak; L C Strong; R E Ferrell; A Trindade
Journal:  Science       Date:  1982-09-03       Impact factor: 47.728

5.  Hereditary renal-cell carcinoma associated with a chromosomal translocation.

Authors:  A J Cohen; F P Li; S Berg; D J Marchetto; S Tsai; S C Jacobs; R S Brown
Journal:  N Engl J Med       Date:  1979-09-13       Impact factor: 91.245

6.  Clinical and surgical aspects of posterior fossa haemangioblastomata.

Authors:  R Jeffreys
Journal:  J Neurol Neurosurg Psychiatry       Date:  1975-02       Impact factor: 10.154

7.  Diagnosis and management of asymptomatic renal cell carcinomas in von Hippel-Lindau syndrome.

Authors:  E Levine; J W Weigel; D L Collins
Journal:  Urology       Date:  1983-02       Impact factor: 2.649

8.  Familial renal carcinoma.

Authors:  F P Li; D J Marchetto; R S Brown
Journal:  Cancer Genet Cytogenet       Date:  1982-11

9.  Mutation and cancer: statistical study of retinoblastoma.

Authors:  A G Knudson
Journal:  Proc Natl Acad Sci U S A       Date:  1971-04       Impact factor: 11.205

10.  The two-mutational-event theory in medullary thyroid cancer.

Authors:  C E Jackson; M A Block; K A Greenawald; A H Tashjian
Journal:  Am J Hum Genet       Date:  1979-11       Impact factor: 11.025

View more
  33 in total

Review 1.  Von Hippel-Lindau disease.

Authors:  E R Maher; A T Moore
Journal:  Br J Ophthalmol       Date:  1992-12       Impact factor: 4.638

2.  Surgical treatment of hemangioblastomas of the central nervous system in pediatric patients.

Authors:  Vassilios I Vougioukas; Sven Gläsker; Ulrich Hubbe; Ansgar Berlis; Heymut Omran; Hartmut P H Neumann; Vera Van Velthoven
Journal:  Childs Nerv Syst       Date:  2005-12-21       Impact factor: 1.475

Review 3.  The molecular basis of von Hippel-Lindau disease.

Authors:  O Iliopoulos; W G Kaelin
Journal:  Mol Med       Date:  1997-05       Impact factor: 6.354

4.  CNS hemangioblastomatosis in a patient without von Hippel-Lindau disease.

Authors:  Arie Franco; Peter Pytel; Rimas V Lukas; Rupa Chennamaneni; John M Collins
Journal:  CNS Oncol       Date:  2017-04

5.  Cryptic von Hippel-Lindau disease: germline mutations in patients with haemangioblastoma only.

Authors:  F J Hes; S McKee; M J Taphoorn; P Rehal; R B van Der Luijt; R McMahon; J J van Der Smagt; D Dow; R A Zewald; J Whittaker; C J Lips; F MacDonald; P L Pearson; E R Maher
Journal:  J Med Genet       Date:  2000-12       Impact factor: 6.318

Review 6.  [Retinal angiomatosis. Ocular manifestation of von Hippel-Lindau disease].

Authors:  B Junker; D Schmidt; H T Agostini
Journal:  Ophthalmologe       Date:  2007-02       Impact factor: 1.059

7.  A novel missense mutation (N78D) in a family with von Hippel-Lindau disease with central nervous system haemangioblastomas, pancreatic and renal cysts.

Authors:  S Cingoz; R B van der Luijt; E Kurt; M Apaydin; I Akkol; Mihriban Heval Ozgen
Journal:  Fam Cancer       Date:  2013-03       Impact factor: 2.375

Review 8.  Somatic mutagenesis in autoimmunity.

Authors:  Thiago Detanico; James B St Clair; Katja Aviszus; Greg Kirchenbaum; Wenzhong Guo; Lawrence J Wysocki
Journal:  Autoimmunity       Date:  2013-01-18       Impact factor: 2.815

9.  Molecular genetic investigations of the mechanism of tumourigenesis in von Hippel-Lindau disease: analysis of allele loss in VHL tumours.

Authors:  P A Crossey; K Foster; F M Richards; M E Phipps; F Latif; K Tory; M H Jones; E Bentley; R Kumar; M I Lerman
Journal:  Hum Genet       Date:  1994-01       Impact factor: 4.132

10.  Physical mapping of chromosome 3p25-p26 by fluorescence in situ hybridisation (FISH).

Authors:  M E Phipps; E R Maher; N A Affara; F Latif; M A Leversha; M E Ferguson-Smith; Y Nakamura; M Lerman; B Zbar; M A Ferguson-Smith
Journal:  Hum Genet       Date:  1993-08       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.